SG Americas Securities LLC Sells 3,212 Shares of Embecta Corp. (NASDAQ:EMBC)

SG Americas Securities LLC cut its position in shares of Embecta Corp. (NASDAQ:EMBC) by 21.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,462 shares of the company’s stock after selling 3,212 shares during the quarter. SG Americas Securities LLC’s holdings in Embecta were worth $237,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. CWM LLC grew its holdings in Embecta by 11.3% during the third quarter. CWM LLC now owns 10,102 shares of the company’s stock worth $142,000 after purchasing an additional 1,023 shares during the period. The Manufacturers Life Insurance Company raised its stake in Embecta by 4.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,212 shares of the company’s stock worth $278,000 after purchasing an additional 1,025 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Embecta by 1.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 145,269 shares of the company’s stock worth $2,048,000 after acquiring an additional 1,600 shares during the period. Natixis Advisors LLC raised its stake in Embecta by 5.7% in the third quarter. Natixis Advisors LLC now owns 30,735 shares of the company’s stock valued at $433,000 after purchasing an additional 1,648 shares in the last quarter. Finally, Quarry LP acquired a new stake in shares of Embecta during the 3rd quarter worth approximately $30,000. Institutional investors own 93.83% of the company’s stock.

Wall Street Analyst Weigh In

EMBC has been the subject of a number of research reports. Morgan Stanley raised shares of Embecta from an “underweight” rating to an “equal weight” rating and increased their target price for the stock from $13.00 to $20.00 in a report on Monday, December 2nd. BTIG Research raised shares of Embecta from a “neutral” rating to a “buy” rating and set a $26.00 price objective on the stock in a research note on Wednesday, November 27th.

Embecta Stock Performance

EMBC stock opened at $17.73 on Friday. The company has a market capitalization of $1.03 billion, a P/E ratio of 13.13, a price-to-earnings-growth ratio of 0.97 and a beta of 1.20. Embecta Corp. has a 52-week low of $9.93 and a 52-week high of $21.48. The business has a 50-day simple moving average of $19.70 and a two-hundred day simple moving average of $16.52.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.20. Embecta had a net margin of 6.97% and a negative return on equity of 18.54%. As a group, sell-side analysts forecast that Embecta Corp. will post 2.84 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 18th. Stockholders of record on Friday, December 6th were given a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 3.38%. The ex-dividend date of this dividend was Friday, December 6th. Embecta’s dividend payout ratio (DPR) is currently 44.44%.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.